Further to its intimation letter dated December 12, 2023, Sun Pharmaceutical Industries has informed that the company (together with its subsidiaries and/or affiliates referred to as ‘Sun Pharma’), have entered into a definitive merger agreement (‘Merger Agreement’) with Taro Pharmaceutical Industries (‘Taro’), pursuant to which Sun Pharma has agreed to acquire all of the outstanding ordinary shares of Taro not currently held by Sun Pharma. The transaction is subject to approvals of the shareholders of Taro, including the majority of its minority shareholders participating in the vote, and subject to other requisite statutory approvals as per the applicable laws. In this connection, it has enclosed the following; Annexure A containing particulars of the disclosure required as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Annexure B is a joint press release of Sun Pharma and Taro which will be released after filing this intimation.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: